Optimizing Vision Restoration: Experience with Holoclar
Treatment, the Selection of a Qualified Treatment Center,
Accessibility to Patients and Outcomes

J 2024

Optimizing Vision Restoration: Experience with Holoclar Treatment, the Selection of a Qualified Treatment Center, Accessibility to Patients and Outcomes

MARINOVA, Cecilia, Eva VLKOVA, Monika HORÁČKOVÁ, Magdalena NETUKOVA, Pavlina SKALICKA et. al.

Základní údaje

Originální název

Optimizing Vision Restoration: Experience with Holoclar Treatment, the Selection of a Qualified Treatment Center, Accessibility to Patients and Outcomes

Autoři

MARINOVA, Cecilia, Eva VLKOVA, Monika HORÁČKOVÁ, Magdalena NETUKOVA, Pavlina SKALICKA, Graziella PELLEGRINI, Veronika SLADKOVA, Martina LOSOVA a Sandra SKVARLOVA

Vydání

Journal of Clinical and Experimental Ophthalmology, Longdom Publishing, 2024, 2155-9570

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizační jednotka

Lékařská fakulta

Změněno: 2. 7. 2024 13:46, Mgr. Tereza Miškechová

Anotace

V originále

Moving towards personalized medicine brings the novel challenge of connecting highly specific treatments with the patients who can benefit from them. One such treatment is the cell therapy Holoclar®, approved for use in adult patients with moderate to severe Limbal Stem Cell Deficiency (LSCD) caused by trauma (burns, chemical burns to the eyes). It takes significant effort and time to establish a qualified Holoclar® Treatment Center (HTC). The efficacy of an HTC is assessed based upon the number of treated patients. We evaluated new approaches to improving patient access to the HTC and thus commercial sustainability for Holoclar®. We mapped new patient pathways and the role of cooperation, networking, coordination among centers and clinical outcomes and focused on the accessibility of Holoclar® across the country. To allow a higher number of patients to be treated, the team successfully implemented a novel approach, patient-doctor tandem travel to utilize an established HTC. Nine patients were treated with Holoclar®, 3 treated patients came from Brno outpatient clinic, 6 patients had previously been treated in other specialized cornea focus centers and traveled to the HTC in tandem with their attending doctor. After one year of follow-up, there was a remarkable improvement in the monitored parameters in all patients. The involvement of an external surgery team required careful procedure planning and additional administration. As it is shown in the case of Holoclar® treatment, not only the experts have to be high-skilled and trained, but before the actual treatment can be initiated, the eligible patients have to be identified, evaluated and effectively transferred to the center. Many processes have to be managed and the complexity of this represents a significant barrier to treatment that should not be underestimated. HTC qualification was made possible by the support of the Medasol team facilitating the process and its administration.

Citovat

MARINOVA, Cecilia, Eva VLKOVA, Monika HORÁČKOVÁ, Magdalena NETUKOVA, Pavlina SKALICKA, Graziella PELLEGRINI, Veronika SLADKOVA, Martina LOSOVA a Sandra SKVARLOVA. Optimizing Vision Restoration: Experience with Holoclar Treatment, the Selection of a Qualified Treatment Center, Accessibility to Patients and Outcomes. Journal of Clinical and Experimental Ophthalmology. Longdom Publishing, 2024. ISSN 2155-9570.

@article{2416329,
   author = {Marinova, Cecilia and Vlkova, Eva and Horáčková, Monika and Netukova, Magdalena and Skalicka, Pavlina and Pellegrini, Graziella and Sladkova, Veronika and Losova, Martina and Skvarlova, Sandra},
   language = {eng},
   issn = {2155-9570},
   journal = {Journal of Clinical and Experimental Ophthalmology},
   title = {Optimizing Vision Restoration: Experience with Holoclar Treatment, the Selection of a Qualified Treatment Center, Accessibility to Patients and Outcomes},
   url = {https://www.longdom.org/open-access/optimizing-vision-restoration-experience-with-holoclar-treatment-the-selection-of-a-qualified-treatment-center-accessibility-to-pa-107069.html},
   year = {2024}
}

TY  - JOUR
ID  - 2416329
AU  - Marinova, Cecilia - Vlkova, Eva - Horáčková, Monika - Netukova, Magdalena - Skalicka, Pavlina - Pellegrini, Graziella - Sladkova, Veronika - Losova, Martina - Skvarlova, Sandra
PY  - 2024
TI  - Optimizing Vision Restoration: Experience with Holoclar Treatment, the Selection of a Qualified Treatment Center, Accessibility to Patients and Outcomes
JF  - Journal of Clinical and Experimental Ophthalmology
PB  - Longdom Publishing
SN  - 21559570
UR  - https://www.longdom.org/open-access/optimizing-vision-restoration-experience-with-holoclar-treatment-the-selection-of-a-qualified-treatment-center-accessibility-to-pa-107069.html
N2  - Moving towards personalized medicine brings the novel challenge of connecting highly specific treatments with the patients who can benefit from them. One such treatment is the cell therapy Holoclar®, approved for use in adult patients with moderate to severe Limbal Stem Cell Deficiency (LSCD) caused by trauma (burns, chemical burns to the eyes). It takes significant effort and time to establish a qualified Holoclar® Treatment Center (HTC). The efficacy of an HTC is assessed based upon the number of treated patients. We evaluated new approaches to improving patient access to the HTC and thus commercial sustainability for Holoclar®. We mapped new patient pathways and the role of cooperation, networking, coordination among centers and clinical outcomes and focused on the accessibility of Holoclar® across the country. To allow a higher number of patients to be treated, the team successfully implemented a novel approach, patient-doctor tandem travel to utilize an established HTC. Nine patients were treated with Holoclar®, 3 treated patients came from Brno outpatient clinic, 6 patients had previously been treated in other specialized cornea focus centers and traveled to the HTC in tandem with their attending doctor. After one year of follow-up, there was a remarkable improvement in the monitored parameters in all patients. The involvement of an external surgery team required careful procedure planning and additional administration. As it is shown in the case of Holoclar® treatment, not only the experts have to be high-skilled and trained, but before the actual treatment can be initiated, the eligible patients have to be identified, evaluated and effectively transferred to the center. Many processes have to be managed and the complexity of this represents a significant barrier to treatment that should not be underestimated. HTC qualification was made possible by the support of the Medasol team facilitating the process and its administration.
ER  -

MARINOVA, Cecilia, Eva VLKOVA, Monika HORÁČKOVÁ, Magdalena NETUKOVA, Pavlina SKALICKA, Graziella PELLEGRINI, Veronika SLADKOVA, Martina LOSOVA a Sandra SKVARLOVA. Optimizing Vision Restoration: Experience with Holoclar Treatment, the Selection of a Qualified Treatment Center, Accessibility to Patients and Outcomes. \textit{Journal of Clinical and Experimental Ophthalmology}. Longdom Publishing, 2024. ISSN~2155-9570.

Podrobný výpis o publikaci